Skip to main content
Top
Published in: Diabetologia 4/2021

Open Access 01-04-2021 | Diabetic Retinopathy | Article

Do Black and Asian individuals wait longer for treatment? A survival analysis investigating the effect of ethnicity on time-to-clinic and time-to-treatment for diabetic eye disease

Authors: Varo Kirthi, Kate I. Reed, Ramith Gunawardena, Komeil Alattar, Catey Bunce, Timothy L. Jackson

Published in: Diabetologia | Issue 4/2021

Login to get access

Abstract

Aims/hypothesis

This study explored the impact of ethnicity on time-to-clinic, time-to-treatment and rates of vision loss in people referred to hospital with diabetic eye disease.

Methods

A survival analysis was performed on all referrals from an inner-city diabetic eye screening programme to a tertiary hospital eye service between 1 October 2013 and 31 December 2017. Exclusion criteria were failure to attend hospital, distance visual acuity in both eyes too low to quantify with the Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart and treatment received prior to referral. Demographic and screening grade data were collected at the point of referral. Small-area statistics and census data were used to calculate indices of multiple deprivation. The main outcome measures were time taken from the date of referral for an individual to achieve the following: (1) attend the first hospital clinic appointment; (2) receive the first macular laser, intravitreal anti-vascular endothelial growth factor injection or pan-retinal photocoagulation treatment, in either eye; and (3) lose at least ten ETDRS letters of distance visual acuity, in either eye.

Results

Of 2062 referrals, 1676 individuals were included. Mean age (± SD) was 57.6 ± 14.7 years, with 52% male sex and 86% with type 2 diabetes. The ethnicity profile was 52% Black, 30% White, 10% Asian and 9% mixed/other, with similar disease severity at the time of referral. Time-to-clinic was significantly longer for Asian people than for Black people (p = 0.03) or White people (p = 0.001). Time-to-treatment was significantly longer for Black people than for White people (p = 0.02). Social deprivation did not significantly influence time-to-treatment. There were no significant differences in the rates of vision loss between ethnic groups.

Conclusions/interpretation

Black people wait longer for hospital eye treatment compared with their White counterparts. The reasons for this delay in treatment warrant further investigation.

Graphical abstract

Appendix
Available only for authorised users
Literature
16.
17.
go back to reference Kerr KJ, Genead MA, Wahlert AJ, Cheetham JK, Hashad Y (2014) Evaluation of the Test-Retest Reliability of the Electronic-ETDRS Visual Acuity Tester. Invest Ophthalmol Vis Sci 55(13):163–163 Kerr KJ, Genead MA, Wahlert AJ, Cheetham JK, Hashad Y (2014) Evaluation of the Test-Retest Reliability of the Electronic-ETDRS Visual Acuity Tester. Invest Ophthalmol Vis Sci 55(13):163–163
27.
go back to reference Angermann R, Rauchegger T, Nowosielski Y et al (2019) Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 257(10):2119–2125. https://doi.org/10.1007/s00417-019-04414-yCrossRef Angermann R, Rauchegger T, Nowosielski Y et al (2019) Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 257(10):2119–2125. https://​doi.​org/​10.​1007/​s00417-019-04414-yCrossRef
29.
go back to reference Rauchegger T, Angermann R, Meusburger A et al (2020) Patient Mobility and Journey Distance as Risk Factors for Severe Visual Impairment: Real-Life Data Analysis of Treatment-naïve Patients with nAMD under Intravitreal Aflibercept Therapy. Klin Monatsbl Augenheilkd 237(6):789–796. [Article in German]. https://doi.org/10.1055/a-1008-9357 Rauchegger T, Angermann R, Meusburger A et al (2020) Patient Mobility and Journey Distance as Risk Factors for Severe Visual Impairment: Real-Life Data Analysis of Treatment-naïve Patients with nAMD under Intravitreal Aflibercept Therapy. Klin Monatsbl Augenheilkd 237(6):789–796. [Article in German]. https://​doi.​org/​10.​1055/​a-1008-9357
31.
Metadata
Title
Do Black and Asian individuals wait longer for treatment? A survival analysis investigating the effect of ethnicity on time-to-clinic and time-to-treatment for diabetic eye disease
Authors
Varo Kirthi
Kate I. Reed
Ramith Gunawardena
Komeil Alattar
Catey Bunce
Timothy L. Jackson
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-020-05364-5

Other articles of this Issue 4/2021

Diabetologia 4/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.